A first-in-class therapeutic that targets neuroactive microbial metabolites in the gut shows promising target engagement, safety and behavioral improvements in adolescents with autism spectrum disorder.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cryan, J. F. et al. Physiol. Rev. 99, 1877–2013 (2019).
Campbell, A. S. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01683-9 (2022).
Needham, B. D. et al. Nature https://doi.org/10.1038/s41586-022-04396-8 (2022).
Swann, J. R., Spitzer, S. O. & Diaz Heijtz, R. Metabolites 10, 172 (2020).
Hsiao, E. Y. et al. Cell 155, 1451–1463 (2013).
Needham, B. D. et al. Biol. Psychiatry 89, 451–462 (2021).
Zheng, Y. et al. Front. Neurosci 15, 738220 (2021).
Hoban, A. E. et al. Transl. Psychiatry 6, e774 (2016).
Phan, B. N. et al. Nat. Neurosci. 23, 375–385 (2020).
Muller, R. A. & Fishman, I. Trends Cogn. Sci. 22, 1103–1116 (2018).
Kujawa, A. et al. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 345–352 (2016).
Tan, Q. et al. Autism Res. 14, 1820–1836 (2021).
Yap, C. X. et al. Cell 184, 5916–5931 e5917 (2021).
Acknowledgements
R.D.H. is supported by the Swedish Research Council, the Swedish Brain Foundation, the Frimurare Barnhus Foundation and the European Union (ITN SmartAge, grant agreement number 859890). P.G. is supported by Inserm, the Université de Paris, the Horizon 2020 Framework Program of the European Union (grant agreement no. 874721/PREMSTEM), the ANR, the Fondation Grace de Monaco, the Fondation des Gueules Cassées and an additional grant from “Investissement d’Avenir-ANR-11-INBS-0011”–NeurATRIS. J.R.S. is supported by the National Institute for Health Research Southampton Biomedical Research Centre, Biotechnology and Biological Sciences Research Council (BB/W00139X/1) and Medical Research Council (MR/W003597/1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Diaz Heijtz, R., Gressens, P. & Swann, J.R. Targeting microbial metabolites to treat autism. Nat Med 28, 448–450 (2022). https://doi.org/10.1038/s41591-022-01711-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01711-8